We are pleased to announce the installation of our new BD FACSLyric Flow Cytometer. Replacing our previous platform, the new system significantly expands our capabilities to 12-colour multiparameter flow cytometry, enabling advanced multiplexing, improved sensitivity and more detailed characterization of complex immune cell populations.
The new platform strengthens our services in:
• Advanced immune cell phenotyping
• T cell, B cell, NK cell and myeloid cell subset characterization
• Immunotoxicology studies
• Biomarker discovery and translational research
• Evaluation of immune responses in efficacy and safety studies
• Cell viability, apoptosis and proliferation assays
• Intracellular cytokine analysis
• Support for cell and gene therapy development
• Expanded capabilities for in vitro and ex vivo assays
This investment further enhances our support for vaccine, biologics and advanced therapeutic development, from early research to non-clinical safety and efficacy studies.